10-1074

BIOLOGICAL7 trials

Sponsors

Rockefeller University, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIVHIV InfectionHIV InfectionsHuman Immunodeficiency VirusHuman Immunodeficiency Virus (HIV)

Phase 1

3BNC117 and 10-1074 in HIV Uninfected Adults

CompletedNCT02824536

Rockefeller UniversityHuman Immunodeficiency Virus

Start: 2016-06-23End: 2018-01-09Updated: 2018-04-17

3BNC117 and 10-1074 in HIV-infected Individuals

CompletedNCT02825797

Rockefeller UniversityHuman Immunodeficiency Virus (HIV)

Start: 2016-06-30End: 2018-08-15Updated: 2018-08-21

3BNC117 and 10-1074 in ART-treated Individuals

CompletedNCT03526848

Rockefeller UniversityHuman Immunodeficiency Virus

Start: 2018-06-05End: 2022-02-11Updated: 2025-10-01

Dual bNAb Treatment in Children

CompletedNCT03707977

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection

Start: 2019-06-17End: 2021-12-03Updated: 2025-05-14

Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions

TerminatedNCT03831945

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2019-04-04End: 2020-12-08Updated: 2021-10-12

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

CompletedNCT03928821

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2019-07-17End: 2021-03-25Updated: 2022-07-11

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Active, not recruitingNCT04340596

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection

Start: 2021-05-21End: 2026-12-30Updated: 2025-03-25

Related Papers

Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study

Clinical Infectious Diseases2025-10-09

Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection

JCI Insight2025-02-235 citations

Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART

PLoS ONE2024-03-274 citations

Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.

2023-10-0126 citations

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.

2022-05-12112 citations

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

2019-08-0871 citations

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.

2018-09-26219 citations